Chembio Diagnostics, Inc. (CEMI) News
Filter CEMI News Items
CEMI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CEMI News Highlights
- For CEMI, its 30 day story count is now at 4.
- Over the past 17 days, the trend for CEMI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CEMI are SA and COMP.
Latest CEMI News From Around the Web
Below are the latest news stories about CHEMBIO DIAGNOSTICS INC that investors may wish to consider to help them evaluate CEMI as an investment opportunity.
Biosynex Completes Acquisition of Chembio Diagnostics, Inc.Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has completed its acquisition of Chembio Diagnostics, Inc. (“Chembio”), a leading point-of-care diagnostics company focused on infectious diseases. Chembio is now part of Biosynex Group. The comp |
Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023Failure to tender shares could result in the termination of the proposed merger between Chembio and BiosynexMEDFORD, N.Y., April 19, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 19, 2023 Fellow Chembio Stockholders, We strongly urge you to tender your shares of common stock of Chembio Diagno |
Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.STRASBOURG, France, April 13, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger Sub, Inc. (“Purchaser”), a Nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the “Shares”) of Chembio Diagnostics, Inc. (Nasd |
Chembio Stockholders Reminded to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023MEDFORD, N.Y., April 10, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 10, 2023 Fellow Chembio Stockholders, As previously communicated, Chembio Diagnostics, Inc. (“Chembio” or the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”), dated as of January 31, 2023, |
Chembio’s CEO Letter to StockholdersReminder to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023MEDFORD, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 3, 2023 Fellow Chembio Stockholders, As previously communicated, Chembio Diagnostics, Inc. (“Chembio” or the “Company”) entered into an Agree |
Chembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 2023MEDFORD, N.Y., March 21, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. Fellow Chembio Stockholders, As previously disclosed, Chembio Diagnostics, Inc. (“Chembio” or the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”), dated as of January 31, 2023, with Biosynex SA, |
Chembio Announces Letter to Stockholders Regarding Tender OfferMEDFORD, N.Y., March 15, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. March 15, 2023 Fellow Chembio Stockholders, As previously disclosed, Chembio Diagnostics, Inc. (“Chembio” or the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”), dated as of January 31, 2023, wit |
Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis SystemMEDFORD, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced receipt of a Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for the DPP HIV-Syphilis System. “The DPP HIV-Syphilis System represents an exciting advancement in rapid testing for sexually transmitted infections. We are excited that the 200,000+ CLIA waived po |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time for another look at the biggest pre-market stock movers worth checking out as we start off trading early on Wednesday! |
French Rapid Testing Company Scoops Up Chembio Diagnostics For $17MPrivately held Biosynex SA has agreed to acquire Chembio Diagnostics Inc (NASDAQ: CEMI) for $0.45 per share in an all-cash transaction valued at $17.2 million. The acquisition combines two rapid diagnostic test companies. Chembio, based in the U.S., focuses on infectious disease assays. Biosynex, based in France, provides a diversified portfolio of rapid tests covering different market segments, including infectious disease and women's health tests, Point of Care devices, and molecular diagnosti |